fbpx

Amniotics – Improved outcome with Pulmostem for lung transplants

Amniotics - Improved outcome with Pulmostem for lung transplants 02 MartsMar 2022 13:00 - 13:30Online Event

Amniotics – Improved outcome with Pulmostem for lung transplants

Amniotics have seen improved outcome with Pulmostem(mesenchymal stem cells from amniotic fluid) in lung transplants.

Amniotics joined CAMP(Centre for Advanced Medical Products) late last year and received a grant from Vinnova (Swedens National Innovation Agency) to build a platform and develop and test a new biological therapy using amniotic fluid-derived stem cells (PulmoStem™) in collaboration with Professor Sandra Lindstedt Ingemansson and her team at CAMP.

Tune in when Amniotics, CEO Kåre Engkilde and leading scientist Professor Sandra Lindstedt Ingemansson from Skåne University Hospital speak on Amniotics'  latest news and pipeline within lung disorder and dive into risks with lung transplantation and current treatments for patients with Acute Lung injury.

Topics Professor Sandra Lindstedt Ingemansson will cover:

  • What is CAMP and CAMP priorities?
  • How does the market for donor lungs look - supply/demand?
  • What side effects are common with today’s treatment?
  • If we assume a positive outcome, what benefits will patients achieve with Pulmostem?

About - Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital - University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics also has also an, by Läkemedelsverket (Swedish MPA in Sweden), approved GMP (Good Manufacturing Practice (GMP) manufacturing facility to produce Advanced therapy Therapy medicinal Medicinal products Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

About - Professor Sandra Lindstedt Ingemansson

Affiliated with the University

Source: Lunds University Research Portal.

Disclaimer: HC Andersen Capital receives payment from Amniotics for a Digital IR / Corporate Visibility subscription agreement.

Deltag her

Du vil blive videresendt til en ekstern tilmeldingsside. 

Information

Amniotics - Improved outcome with Pulmostem for lung transplants 02 MartsMar 2022 13:00 - 13:30
Amniotics - Improved outcome with Pulmostem for lung transplants Online Event
Amniotics
Amniotics - Improved outcome with Pulmostem for lung transplants 02 MartsMar 2022 13:00 - 13:30Online Event

Amniotics – Improved outcome with Pulmostem for lung transplants

Amniotics have seen improved outcome with Pulmostem(mesenchymal stem cells from amniotic fluid) in lung transplants.

Amniotics joined CAMP(Centre for Advanced Medical Products) late last year and received a grant from Vinnova (Swedens National Innovation Agency) to build a platform and develop and test a new biological therapy using amniotic fluid-derived stem cells (PulmoStem™) in collaboration with Professor Sandra Lindstedt Ingemansson and her team at CAMP.

Tune in when Amniotics, CEO Kåre Engkilde and leading scientist Professor Sandra Lindstedt Ingemansson from Skåne University Hospital speak on Amniotics'  latest news and pipeline within lung disorder and dive into risks with lung transplantation and current treatments for patients with Acute Lung injury.

Topics Professor Sandra Lindstedt Ingemansson will cover:

  • What is CAMP and CAMP priorities?
  • How does the market for donor lungs look - supply/demand?
  • What side effects are common with today’s treatment?
  • If we assume a positive outcome, what benefits will patients achieve with Pulmostem?

About - Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital - University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics also has also an, by Läkemedelsverket (Swedish MPA in Sweden), approved GMP (Good Manufacturing Practice (GMP) manufacturing facility to produce Advanced therapy Therapy medicinal Medicinal products Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

About - Professor Sandra Lindstedt Ingemansson

Affiliated with the University

Source: Lunds University Research Portal.

Disclaimer: HC Andersen Capital receives payment from Amniotics for a Digital IR / Corporate Visibility subscription agreement.

Information

Amniotics - Improved outcome with Pulmostem for lung transplants 02 MartsMar 2022 13:00 - 13:30
Amniotics - Improved outcome with Pulmostem for lung transplants Online Event
Amniotics